SCIENTURE Secures Formulary Coverage for REZENOPY™ with a Large National Health Plan and Expands Commercial Team
Rhea-AI Summary
Scienture (NASDAQ: SCNX) announced that REZENOPY™ (naloxone HCl) Nasal Spray 10 mg has been added to the formulary of a large national health plan, extending potential coverage to over 100 million lives ahead of a planned mid-July 2026 U.S. commercial launch.
REZENOPY™, the highest FDA-approved naloxone dose per nasal spray in the U.S., targets a naloxone market of about $144 million and 9.8 million units annually. Existing GPO agreements provide access across 5,000+ facilities, representing roughly 60% of the institutional naloxone market, supported by an expanded sales team.
AI-generated analysis. Not financial advice.
Positive
- Formulary coverage extends REZENOPY™ access to over 100 million covered lives
- GPO agreements provide REZENOPY™ access at 5,000+ facilities, ~60% institutional market
- Planned U.S. commercial launch of REZENOPY™ in mid-July 2026
- REZENOPY™ offers highest FDA-approved naloxone dose per nasal spray in U.S.
- Targets U.S. naloxone market of ~$144 million and 9.8 million units annually
- Exclusive U.S. commercialization rights to REZENOPY™ from Summit Biosciences
Negative
- None.
Market Reaction – SCNX
Following this news, SCNX has declined 4.46%, reflecting a moderate negative market reaction. Our momentum scanner has triggered 12 alerts so far, indicating notable trading interest and price volatility. The stock is currently trading at $0.34. This price movement has removed approximately $668K from the company's valuation. Trading volume is elevated at 2.6x the average, suggesting increased selling activity.
Data tracked by StockTitan Argus (15 min delayed). Upgrade to Gold for real-time data.
Key Figures
Market Reality Check
Peers on Argus
Pre-news, SCNX traded slightly lower while momentum scanner peers showed mixed moves, with 3 down and 1 up. Sector names like HKPD and BLRX in the scanner moved mostly lower, suggesting this commercial access update is more stock-specific than part of a broad sector trend.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Jun 04 | Conference participation | Neutral | +0.0% | Announcement of presentation at a small-cap showcase with webcast and meetings. |
| Jun 02 | Patent grant | Positive | -1.4% | U.S. patent granted for REZENOPY 10 mg nasal spray, extending IP to 2041. |
| May 18 | Earnings update | Positive | -2.3% | Q1 2026 revenue and margin expansion with ongoing net losses and debt financing. |
| May 07 | Debt financing | Positive | +8.6% | Secured $11.0M in non-dilutive debt to fund commercialization and R&D pipeline. |
| May 06 | Patent grant | Positive | +0.1% | Third patent for ARBLI oral suspension, protecting market exclusivity through 2041. |
Recent positive IP, financing, and product updates have often seen muted or even negative next-day moves, with only the non-dilutive debt financing triggering a stronger positive reaction.
Over the past months, Scienture has transitioned toward commercialization while building the REZENOPY™ and ARBLI™ franchises. Key milestones included new patents for both products, non-dilutive debt financing of $11.0 million, and early revenue growth with high gross margins but ongoing losses. Prior REZENOPY updates emphasized patent protection, GPO access to over 5,000 institutions, and a mid-July 2026 launch target. Today’s formulary and coverage news extends that commercialization path by adding large-plan access and expanding the field team.
Regulatory & Risk Context
The company has an active Form S-3 shelf registration filed on 2025-08-01, noted as not yet effective and used in connection with at least 4 prospectus supplements. This structure provides pre-established flexibility to raise capital as needed, subject to effectiveness and market conditions.
Market Pulse Summary
This announcement highlights a key commercialization step for REZENOPY™, with formulary coverage at a large national health plan and GPO agreements reaching over 5,000 facilities, potentially touching more than 100 million covered lives. It builds on earlier IP and access milestones ahead of a planned mid-July 2026 launch into a roughly $144 million U.S. naloxone market. Investors may track execution on adoption, revenue growth versus ongoing losses, and future financing decisions under the existing capital structure.
Key Terms
formulary financial
group purchasing organization financial
gpo financial
naloxone medical
fda-approved regulatory
commercialization rights financial
nasal spray medical
AI-generated analysis. Not financial advice.
Commercial Launch Planned for Mid-July; 5,000+ Healthcare Facilities Reached Through GPO Agreements, Covering ~
U.S. naloxone market totals ~
COMMACK, NY, June 09, 2026 (GLOBE NEWSWIRE) -- SCIENTURE HOLDINGS, INC. (NASDAQ: SCNX) (“Scienture”), a holding company for existing and planned pharmaceutical operating companies focused on providing enhanced value to patients, physicians and caregivers through the development, commercialization, and distribution of novel specialty products that address unmet market needs, today announced that REZENOPY™ (naloxone HCl) Nasal Spray 10 mg has been added to the formulary of a large national health plan, expanding access through commercial and Medicare supplemental coverage.
REZENOPY™ is the highest FDA-approved naloxone dose per nasal spray available in the United States, delivering 10 mg of naloxone HCl in a single-use nasal spray device for the emergency treatment of known or suspected opioid overdose. The product leverages the proven naloxone hydrochloride molecule and familiar nasal spray form factor, while delivering increased effectiveness against potent opioids. According to IQVIA data (MAT April 2026), total annual U.S. naloxone sales reached approximately
Scienture is working to commercialize REZENOPY™ through a multi-channel strategy targeting institutional, government and commercial customers, including hospitals, health systems, emergency medical services (EMS) providers, rehabilitation centers, pharmacies and other healthcare organizations.
In addition, Scienture has expanded its commercial organization with the addition of three new sales representatives to support the nationwide rollout of REZENOPY™ and to help accelerate adoption across key institutional and commercial markets.
As previously announced in March 2026, Scienture secured Group Purchasing Organization (GPO) agreements providing commercial access for REZENOPY™ across more than 5,000 healthcare facilities. These agreements help expand the product's institutional footprint, creating the potential to penetrate more than
“We have built a strong commercial foundation for the launch of REZENOPY™, with expanding payer coverage, broad institutional access and a growing field organization,” said Narasimhan Mani, President and co-CEO of Scienture. “The addition of a large national health plan, combined with our GPO agreements covering more than 5,000 institutions, significantly enhances our ability to reach patients, healthcare providers and first responders across the country. As we approach our planned mid-July launch, we believe REZENOPY™ is well positioned for broad market adoption.”
Shankar Hariharan, Executive Chairman and co-CEO of Scienture, added, “REZENOPY™ enters a large and growing naloxone market with a differentiated profile as the highest FDA-approved naloxone dose per nasal spray available in the United States. With institutional reach across hospitals, EMS providers and rehabilitation centers, and an expanding commercial team, we are executing on a comprehensive market access strategy designed to maximize awareness, availability and adoption of REZENOPY™ nationwide. We believe REZENOPY™ has the potential to become an important tool in the fight against opioid overdose and help expand access to life-saving intervention when every second counts.”
As previously disclosed, Scienture, LLC, a wholly-owned subsidiary of Scienture Holdings, Inc., entered into a definitive agreement with Summit Biosciences Inc. (a Kindeva subsidiary) in March 2025, for the exclusive U.S. commercialization rights to REZENOPY™ (naloxone HCl) Nasal Spray 10 mg, which received FDA approval on April 19, 2024.
About REZENOPY™
REZENOPY™ (naloxone HCl) Nasal Spray 10mg, is an opioid antagonist indicated for the emergency treatment of known or suspected opioid overdose, as manifested by respiratory and/or central nervous system depression in adult and pediatric patients. It is intended for immediate administration as emergency therapy in settings where opioids may be present.
REZENOPY™ nasal spray is for intranasal use only and is supplied as a carton containing two (2) blister packages each with a single spray device.
IMPORTANT SAFETY INFORMATION
- Administration: REZENOPY™ nasal spray is for intranasal use only. Seek emergency medical care immediately after use. Administer a single spray into one nostril. If the patient does not respond within 2 to 3 minutes or responds and then relapses into respiratory depression, an additional dose may be given into the other nostril with a new device. Do not administer more than 2 sprays per day. Additional supportive and/or resuscitative measures may be helpful while awaiting emergency medical assistance.
- Contraindications: REZENOPY™ nasal spray is contraindicated in patients known to be hypersensitive to naloxone hydrochloride or to any of the other ingredients.
- Warnings and Precautions:
- Risk of Recurrent Respiratory and CNS Depression: Due to the duration of action of naloxone relative to the opioid, keep the patient under continued surveillance and administer additional doses as necessary while awaiting emergency medical assistance.
- Risk of Limited Efficacy with Partial Agonists or Mixed Agonists/Antagonists: Reversal of respiratory depression caused by partial agonists or mixed agonists/antagonists, such as buprenorphine and pentazocine, may be incomplete. Larger or repeat doses may be required.
- Precipitation of Severe Opioid Withdrawal: Use in patients who are opioid-dependent may precipitate opioid withdrawal. In neonates, opioid withdrawal may be life-threatening if not recognized and properly treated. Monitor for the development of opioid withdrawal.
- Risk of Cardiovascular Effects: Abrupt postoperative reversal of opioid depression may result in adverse cardiovascular effects. These events have primarily occurred in patients who had pre-existing cardiovascular disorders or received other drugs that may have similar adverse cardiovascular effects. Monitor these patients closely in an appropriate healthcare setting after use of naloxone hydrochloride.
- Adverse Reactions: The following adverse reactions were observed in a REZENOPY™ nasal spray clinical study: upper abdominal pain, nasopharyngitis, and dysgeusia.
- Storage and Handling: Store REZENOPY™ nasal spray in the blister and cartons provided. Store between 2°C to 25°C (36°F to 77°F). Excursions permitted up to 40°C (104°F). Do not freeze or expose to excessive heat above 40°C (104°F). Protect from light. REZENOPY™ nasal spray may freeze at cold temperatures. If this happens, the device will not spray. If REZENOPY™ nasal spray is frozen and is needed in an emergency, do NOT wait for it to thaw; get emergency medical help right away.
For more detailed information, please refer to the full prescribing information provided by the FDA.
About Scienture Holdings, Inc.
SCIENTURE HOLDINGS, INC. (NASDAQ: “SCNX”), through its wholly owned subsidiary, Scienture, LLC, is a comprehensive pharmaceutical product company focused on providing enhanced value to patients, physicians and caregivers by offering novel specialty products to satisfy unmet market needs. Scienture, LLC is a branded, specialty pharmaceutical company consisting of a highly experienced team of industry professionals who are passionate about developing and bringing to market unique specialty products that provide enhanced value to patients and healthcare systems. The assets in development at Scienture are across therapeutics areas, indications and cater to different market segments and channels. For more information please visit: www.scientureholdings.com and www.scienture.com.
Cautionary Statements Regarding Forward-Looking Statements
This press release contains certain statements that may be deemed to be “forward-looking statements” within the federal securities laws, including the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. Statements that are not historical are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements relate to future events or our future performance or future financial condition. These forward-looking statements are not historical facts, but rather are based on current expectations, estimates and projections about our company, our industry, our beliefs and our assumptions. Such forward-looking statements include, but are not limited to, statements regarding our or our management team’s expectations, hopes, beliefs, intentions or strategies regarding the future, including for the products we may launch, such as REZENOPY™, the success those products may have in the marketplace, and our strategies related to those products. In addition, any statements that refer to projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. In some cases, you can identify forward-looking statements by the following words: “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “ongoing,” “plan,” “potential,” “predict,” “project,” “should,” or the negative of these terms or other similar expressions, but the absence of these words does not mean that a statement is not forward-looking. Forward-looking statements are subject to a number of risks and uncertainties (some of which are beyond our control) that may cause actual results or performance to be materially different from those expressed or implied by such forward-looking statements. Accordingly, readers should not place undue reliance on any forward-looking statements. These risks include risks relating to agreements with third parties; our ability to raise funding in the future, as needed, and the terms of such funding, including potential dilution caused thereby; our ability to continue as a going concern; security interests under certain of our credit arrangements; our ability to maintain the listing of our common stock on the Nasdaq Capital Market; claims relating to alleged violations of intellectual property rights of others; the outcome of any current legal proceedings or future legal proceedings that may be instituted against us; unanticipated difficulties or expenditures relating to our business plan; and those risks detailed in our most recent Annual Report on Form 10-K and subsequent reports filed with the SEC.
Forward-looking statements speak only as of the date they are made. Scienture Holdings, Inc. undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise that occur after that date, except as otherwise provided by law.
Contact:
SCIENTURE HOLDINGS, INC.
20 Austin Blvd
Commack, NY 11725
Phone: (866) 468-6535
Email: IR@Scienture.com
